Alexion Pharmaceuticals: Growth At A Reasonable Price (GARP)
How pharmaceutical company Alexion set the price of the world's most expensive drug | CBC News
With approval for new drug, Alexion aims to switch patients from Soliris
MDA Celebrates FDA Approval of Alexion's Ultomiris for Treatment of gMG
Alexion, Vertex rare disease drugs fare well in new rare disease drug report - Boston Business Journal
Medicines | Alexion
The Innovative Medicines Fund: A catalyst to drive access to rare disease treatments? September 2021
Drug company Alexion's shares plunge after CEO, CFO exit
Medicines | Alexion
U.S. drug company sues Canada for trying to lower cost of $700K-a-year drug | CBC News
Alexion trials rare disease drug Ultomiris in severe COVID-19 cases | Pharmaphorum
Canadian Drug Watchdog Orders Alexion to Lower Price of Soliris, Refund Overcharges - Global Genes
Alexion Pharmaceuticals: Revising My Valuation (NASDAQ:ALXN) | Seeking Alpha
Five years later, Alexion sets aside $25M to resolve SEC's foreign bribery probe | Fierce Pharma
Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics™ for Rare Diseases | Business Wire
Alexion Says FDA Grants Orphan Drug Designation To ALXN1210 | World Pharma Today
Alexion Pharmaceuticals: Patented Quality at a Great Price | by Shivam Kollur | Medium
Handok's 2023 turnover to drop sharply as AZ retrieves sales rights < Pharma < Article - KBR
AstraZeneca drug added in Alexion acquisition falls short in pivotal ALS trial - MedCity News
Can Alnylam execs put the biotech on a path to profitability? - Boston Business Journal
AstraZeneca + Alexion = Rescue of Both Companies • BioPharma Media
Alexion Pharmaceuticals Marketed Drugs - GlobalData
AstraZeneca to acquire Alexion for $39B - Drug Discovery and Development
NICE rejects second Alexion ultra-rare disease drug | Pharmaphorum
Alexion crowns myasthenia gravis as its best Soliris launch ever | Fierce Pharma
New Alexion rare-disease drug wins FDA approval | New Haven BIZ
AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal | Reuters
